BrightPath Biotherapeutics
4594.TTSE GROWTHPharmaceutical
Filed as BrightPath Biotherapeutics Co., Ltd (2022-06–2026-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥84,000 | ¥1m | ¥72,000 | ¥5m | ¥15m | ¥3m |
| Operating income | −¥1.3bn | −¥1.2bn | −¥1.2bn | −¥1.5bn | −¥1.5bn | −¥1.7bn |
| Ordinary income | −¥1.3bn | −¥1.1bn | −¥1.2bn | −¥1.5bn | −¥1.5bn | −¥1.7bn |
| Total assets | ¥2.6bn | ¥1.1bn | ¥1.2bn | ¥1.7bn | ¥2.8bn | ¥3.7bn |
| Net assets / equity | ¥2.4bn | ¥925m | ¥979m | ¥1.6bn | ¥2.5bn | ¥3.5bn |
| Operating cash flow | −¥1.4bn | −¥1.3bn | −¥1.2bn | −¥1.2bn | −¥1.5bn | −¥1.8bn |
| EPS (basic) | ¥-11.7 | ¥-14.12 | ¥-18.21 | ¥-24.9 | ¥-28.55 | ¥-36.14 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2017-04-01 → 2018-03-31 | AnnualAmended | 152 figures · EDINET |
21 more reports are still being processed.